Last reviewed · How we verify
NCT04736160
Pilot Study: hCG Secreted by Blastocyst as Potential Marker of Embryo Quality
trial testing collect data in Embryo Disorder in 60 participants. Status unknown.
25 November 2019
Quick facts
| Lead sponsor | IVI Vigo |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 5 December 2018 |
| Primary completion | 25 November 2019 |
| Estimated completion | 25 November 2021 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- collect data
Conditions studied
- Embryo Disorder — all drugs for Embryo Disorder →
Sponsor
IVI Vigo
Who can join
Adults 18 to 41, female only, with Embryo Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
hCG is a hormone produced very early by the pre-embryo, but not by the oocyte. It has a pivotal role in the trophoblast differentiation, and embryo implantation as well as the corpus luteum support. In spite of its well-known role, the literature about it is scarce. The aim of this study is to evaluate the relation between the amount of hCG secreted by the blastocyst and embryo euploidy status and morphological pre-embryo quality according to morphokinetic pattern. We will analyse the amount of hCG secreted by blastocyst to the culture medium thorough mass spectrometry and it will be correlated with the main morphokinetic issues and the chromosomal structure after NGS analysis at blastocyst stage. We will take the pre-embryo spent culture medium that has been discarded after embryo culture without any interference on the pre-embryo neither any different deviation of standard protocol of embryo manipulation. Furthermore, the evaluation by time-lapse technology will let to document the main issues of embryo development, also without any deviation of the standard protocol. We are waiting to find the value of hCG secreted by blastocyst as a potential marker of embryo quality and ploidy status.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04736160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of collect data
Trials testing the same drug.
- NCT05875363 — Neurodevelopmental Disorders in Youth With Criminal Behaviors · completed
Other IVI Vigo trials
Trials by the same sponsor.
- NCT04734769 — Embryos With Preimplantation Genetic Testing for Aneuploidies (PGT-A) Inconclusive Result: Clinical Implications · unknown
- NCT04549909 — Biochemical Pregnancy Loss. A Multicenter Retrospective Study · completed
- NCT04744519 — hCG Concentration in Peripheral Maternal Blood After Embryo Transfer, Ongoing Pregnancy Rates, and Morphokinetics · completed
- NCT04571671 — Do müllerian Anomalies Affect Embryo Implantation? · completed
- NCT04574310 — Does the Air-bubble Location Influence on the Implantation Rate · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04736160 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IVI Vigo
- Last refreshed: 4 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04736160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing